{
  "abstract": "This article describes a case of warm autoimmune haemolytic anaemia (w-AIHA) in a 16-month-old refractory to first-line treatment. W-AIHA typically responds to systemic corticosteroids. Here, management proved challenging with re-emergence of haemolysis during initial steroid course. Rituximab offered a turning point, demonstrating the utility of targeted anti-CD20 antibody therapy in achieving a sustained haematological response. The patient’s clinical course was not without further complications potentially attributable to treatments administered. This paper reviews the management of w-AIHA, beyond steroid therapy, with an additional focus on supportive care measures.",
  "authors": [
    {
      "affiliations": [
        "Children’s Haematology Unit, Royal Belfast Hospital for Sick Children, Belfast, UK",
        "Queen’s University Belfast, Belfast, UK"
      ],
      "name": "Emilie Clifton"
    },
    {
      "affiliations": [
        "Children’s Haematology Unit, Royal Belfast Hospital for Sick Children, Belfast, UK"
      ],
      "name": "Niamh McCool"
    },
    {
      "affiliations": [
        "Children’s Haematology Unit, Royal Belfast Hospital for Sick Children, Belfast, UK"
      ],
      "name": "Bethany Mitchell"
    },
    {
      "affiliations": [
        "Children’s Haematology Unit, Royal Belfast Hospital for Sick Children, Belfast, UK"
      ],
      "name": "Catherine Mark"
    }
  ],
  "title": "Breaking the heat: managing steroid refractory warm autoimmune haemolytic anaemia",
  "uid": "47491cc2-f05c-57a8-8d6d-00f5f47c49d5"
}